Genelux Corporation (GNLX) vs Spruce Biosciences, Inc. (SPRB)
A side-by-side comparison of Genelux Corporation and Spruce Biosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GNLX
Genelux Corporation
$2.54HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SPRB
Spruce Biosciences, Inc.
$42.79HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — GNLX vs SPRB
growth of $100 · dividends reinvested · last 4yGNLX -57.7% (-19.4%/yr)SPRB -78.3% (-31.7%/yr)GNLX compounded faster over this window
GNLX SPRB
GNLX vs SPRB: by the numbers
- •SPRB is the larger company ($118M vs $114M market cap).
- •Both run net losses; SPRB's is the smaller (0.00% vs -422412.50% net margin).
Metrics side by side
Valuation
| Metric | GNLX | SPRB |
|---|---|---|
| P/S ratio | 14236.83 | N/A |
| P/B ratio | 7.07 | 1.41 |
Profitability
| Metric | GNLX | SPRB |
|---|---|---|
| Gross margin | -7075.00% | 0.00% |
| Operating margin | -415175.00% | 0.00% |
| Net margin | -422412.50% | 0.00% |
| ROE | -209.73% | -61.33% |
| ROIC | -192.18% | -50.67% |
Growth (annualized)
| Metric | GNLX | SPRB |
|---|---|---|
| Total return CAGR (5Y) | N/A | -36.23% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.